These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25539259)

  • 1. Breast MRI-detected cystic apocrine metaplasia: imaging features with microvessel analysis and histologic correlation.
    diFlorio-Alexander RM; Marotti JD; Bond JS; Schwab MC; Memoli VA; Wells WA; Poplack SP
    AJR Am J Roentgenol; 2015 Jan; 204(1):211-8. PubMed ID: 25539259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apocrine Metaplasia Found at MR Biopsy: Is There Something to be Learned?
    Gao Y; Dialani V; DeBenedectis C; Johnson N; Brachtel E; Slanetz P
    Breast J; 2017 Jul; 23(4):429-435. PubMed ID: 28079289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillary and sclerosing lesions of the breast detected and biopsied by MRI: Clinical management, upgrade rate, and association with apocrine metaplasia.
    Ring NY; diFlorio-Alexander RM; Bond JS; Rosenkranz KM; Cervantes E; Sohn JH; Marotti JD
    Breast J; 2019 May; 25(3):393-400. PubMed ID: 30945398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uneven distribution and significant concentration of apocrine metaplasia in lower breast quadrants.
    Benigni G; Squartini F
    Tumori; 1986 Apr; 72(2):179-82. PubMed ID: 3705191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-operative breast pathology: apocrine lesions.
    Wells CA; El-Ayat GA
    J Clin Pathol; 2007 Dec; 60(12):1313-20. PubMed ID: 18042688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Histologic Spectrum of Apocrine Lesions of the Breast.
    Durham JR; Fechner RE
    Am J Clin Pathol; 2000 May; 113(suppl_1):S3-18. PubMed ID: 11993707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine metaplasia: mammographic and sonographic appearances.
    Warner JK; Kumar D; Berg WA
    AJR Am J Roentgenol; 1998 May; 170(5):1375-9. PubMed ID: 9574619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammographic-pathologic correlation of apocrine metaplasia diagnosed using vacuum-assisted stereotactic core-needle biopsy: our 4-year experience.
    Kushwaha AC; O'Toole M; Sneige N; Stelling CB; Dryden MJ
    AJR Am J Roentgenol; 2003 Mar; 180(3):795-8. PubMed ID: 12591698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Apocrine lesions in breast pathology].
    Suciu V; Menet E; Guinebretière JM; Trassard M; Vielh P
    Ann Pathol; 2009 Nov; 29 Spec No 1():S112-3. PubMed ID: 19887237
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathologic Findings of Breast Lesions Detected on Magnetic Resonance Imaging.
    Jabbar SB; Lynch B; Seiler S; Hwang H; Sahoo S
    Arch Pathol Lab Med; 2017 Nov; 141(11):1513-1522. PubMed ID: 28782985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts.
    Wellings SR; Alpers CE
    Hum Pathol; 1987 Apr; 18(4):381-6. PubMed ID: 3557440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.
    Asirvatham JR; Falcone MM; Kleer CG
    Arch Pathol Lab Med; 2016 Oct; 140(10):1045-51. PubMed ID: 27684975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphologic and functional aspects of apocrine metaplasia in dysplastic and neoplastic breast tissue.
    Bussolati G; Cattani MG; Gugliotta P; Patriarca E; Eusebi V
    Ann N Y Acad Sci; 1986; 464():262-74. PubMed ID: 3524352
    [No Abstract]   [Full Text] [Related]  

  • 16. Fibroadenoma of the breast: analysis of associated pathological entities--a different risk marker in different age groups for concurrent breast cancer.
    Shabtai M; Saavedra-Malinger P; Shabtai EL; Rosin D; Kuriansky J; Ravid-Megido M; Ben Haim M; Ayalon AH
    Isr Med Assoc J; 2001 Nov; 3(11):813-7. PubMed ID: 11729575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
    Shim HS; Jung WH; Kim H; Park K; Cho NH
    APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.
    Selim AG; Wells CA
    J Clin Pathol; 1999 Nov; 52(11):838-41. PubMed ID: 10690175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
    Selim AG; El-Ayat G; Wells CA
    Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image cytometry in nonproliferative fibrocystic breast changes. Ploidy evaluation and epidemiologic study.
    Azúa-Romeo J; de Azúa-Blanco J; Romeo P
    Anal Quant Cytol Histol; 2001 Apr; 23(2):129-34. PubMed ID: 11332079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.